01.22.2019 Issue 435

Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

HealthCore-NERI’s Singer Talks RWE,
Pragmatic Clinical Trials

Monday, January 21

HealthEconomics.Com Founder and CEO Dr. Patti Peeples recently discussed with HealthCore-NERI CMO Dr. Joseph Singer the impact of pragmatic clinical trials on real-world evidence (RWE).

Pharmerit Expands Market Access Support in Asia

NorthShore, Color Partner to Implement Genomic Data for 10K Patients

United Healthcare Sues Pharma Companies

Lack of Standardized Definition of Value Detrimental to Push, Article Says

Despite Much Health Care Data, Obstacles Complicate Their Use

Opinion: U.S. Shouldn’t Outsource Drug Value Assessments Through an IPI

Report: Medicare Part D Could Have Saved $14.4 Billion in 2016 by Negotiating to VA Prices

Healthcare Data Scientist

Sr. Director, Health Economics and Outcomes Research

Director, Statistics - Real-World Evidence (Flexible Location)

Managing Consultant – Market Access Consulting (Waltham, MA)

Industry Spotlight

Conferences Webinars
Reimbursement and Contracting
    January 23-24, Philadelphia, Pennsylvania

Data Analytics and Decisions
    January 23-24, Philadelphia, Pennsylvania

Special Therapies 2019
    January 24-25, Las Vegas, Nevada

The Payer and Provider Ecosystem Evolution
    January 27-30, San Diego, California

AI and the Augmented Age in Health Care
    January 23

Prove it with PROs?
    January 24

HEOR & RWE: Global Sourcing Strategies and Best Practices
    January 24

Statistical Learning: What Is It? How Does It Relate to Machine Learning and AI? How is It Applied in Healthcare?
    January 30

Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

HTA in Europe: Key Success Factors for Positive HTA Recommendations

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)

From Patent to Patient: Analyzing Access to Innovative Cancer Drugs

Transitioning Payment Models: Fee-for-Service to Value-Based Care

Special Thanks to Our Partners:
               Evidera   HealthCore  
      University of FL   Xcenda  OM1    Parexel   Jefferson
      Dymaxium   Precision Xtract    Pharmerit    eMax Health
      Sciformix   Evidence Partners    ICON    Truven
Share this newsletter on social media:

Email Twitter Facebook LinkedIn